Cited by 12Neuroinflammation and Neurodegeneration MechanismsGenomics and Chromatin DynamicsMultiple Sclerosis Research Studies

Transcription factors that define the epigenome structures and transcriptomes in microglia

Open access
Saeki, Keita, Ozato, Keiko·2025·Experimental Hematology

Abstract

Microglia, the resident macrophages of the brain, play critical roles in maintaining brain health. Recent genome-wide analyses, including ATAC-seq, ChIP-seq/CUT&RUN, and single-cell RNA-seq, have identified key transcription factors that define the transcriptome programs of microglia. Four transcription factors-PU.1, Irf8, Sall1, and Smad4-form enhancer complexes and act as lineage-determining factors, shaping microglial identity. These factors co-bind with other lineage-determining transcription factors, directing one toward designated regions that program microglia while inhibiting the other from binding to DNA. Other transcription factors, such as Batf3 and Mafb, contribute to transcriptional cascades in microglia. TGF-β is a crucial cytokine driving these transcription factors to bind DNA and maintain homeostatic microglia. These findings provide insights into the physiological aspects of microglia and their roles in neuroinflammatory and neurodegenerative diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.exphem.2025.104814

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SPI1, encoding PU.1, is a key determinant of microglial identity and disease responsiveness.

    “Among the regulatory nodes controlling these states, SPI1, which encodes the myeloid transcription factor PU.1, has emerged as a key determinant of microglial identity and disease responsiveness.”

    From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [26]

    The PU.1 section (page unavailable) identifies Spi1 as encoding PU.1 and describes PU.1 as essential to microglia and involved in enhancers that regulate cellular identity. It also describes a disease-associated-like phenotype after deletion of an enhancer bound by several factors, but does not establish PU.1 itself as a key determinant of disease responsiveness. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • SPI1 is a regulatory node capable of shaping many downstream immune, phagocytic, lipid-handling, and inflammatory pathways at once.

    “This means that SPI1 is not simply another Alzheimer ’s-associated gene; it is a regulatory node capable of shaping many downstream immune, phagocytic, lipid-handling, and inflammatory pathways at once.”

    From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [26]

    The PU.1 section (page unavailable) identifies PU.1 as encoded by SPI1 and describes it as a transcriptional activator upstream of IRF8, supporting its role as a regulatory node. The copy does not establish that SPI1 shapes all four specified downstream pathways—particularly lipid-handling and phagocytic pathways—at once. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • In the brain, PU.1 helps organize the enhancer landscape that allows microglia to maintain their identity, respond to environmental signals, and activate disease-relevant gene programs.

    “In the brain, PU.1 helps organize the enhancer landscape that allows microglia to maintain their identity, respond to environmental signals, and activate disease-relevant gene programs.”

    From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [26]

    The PU.1 section (page unavailable) describes PU.1 as a component of microglial super-enhancers and says its enhancer-promoter interactions occur at genes that define microglia, supporting the identity claim. It does not establish that PU.1 enables responses to environmental signals or activates disease-relevant gene programs. Instead, the Conclusions assign responses to external cues to SMAD4, while the PU.1 section reports DAM-like gene expression after deletion of a super-enhancer. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • PU.1 belongs to the ETS family of transcription factors and is central to myeloid lineage specification, including the development and functional identity of macrophages and microglia.

    “PU.1 belongs to the ETS family of transcription factors and is central to myeloid lineage specification, including the development and functional identity of macrophages and microglia.”

    From Lymphoid-like Suppressive Microglia in Alzheimer’s Disease: A New Neuroimmune Regulatory Axis? (2026) · cites this paper as [26]

    The PU.1 section identifies PU.1 as an Ets-family transcription factor and describes its role in hematopoietic cell fate and microglial identity. “A stepwise development of microglia” also says microglial progenitors emerge through PU.1-dependent pathways. Our copy does not establish the same developmental and functional-identity role for macrophages generally. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [28]Nott A. Brain cell type-specific enhancer-promoter interactome maps and diseaserisk association. Science 366, 1134– 1139 (2019). 31727856 PMC7028213
  2. [48]Engels S, Kohlhase J & McGaughran J A SALL1 mutation causes a branchio-oto-renal syndrome-like phenotype. J Med Genet 37, 458– 460 (2000). 10928856 PMC1734618

Cited by

Sorted by citations

Authors
Saeki, K., & Ozato, K.
Affiliations
National Institutes of Health (US)
Corresponding author
  • Saeki, Keita
  • Ozato, Keiko
Venue
Experimental Hematology
Publisher
Elsevier BV
Published
2025-09
Volume
149
Pages
104814
ISSN
0301-472X (ISSN-L)
OpenAlex
W4410717078
Cited by
11
References
92
Citations by year
2026: 9 · 2025: 2
FWCI
1.07
Type
journal article
Language
en
Open access
Locations
  • Experimental Hematology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Funders
Kumamoto University
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
microglia, transcription factors, microglial transcriptome, epigenome, PU.1, IRF8, SALL1, SMAD4, Batf3, MAFB, lineage determination, TGF-beta signaling, neuroinflammation, neurodegenerative diseases, transcriptional cascade
MeSH terms
Epigenome, Animals, Humans, Transcription Factors, Transforming Growth Factor beta, Microglia, Neurodegenerative Diseases, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review